1. Home
  2. EVAX vs PPBT Comparison

EVAX vs PPBT Comparison

Compare EVAX & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EVAX

Evaxion Biotech

HOLD

Current Price

$5.15

Market Cap

42.7M

Sector

Health Care

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.70

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVAX
PPBT
Founded
2008
2010
Country
Denmark
Israel
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.7M
7.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
EVAX
PPBT
Price
$5.15
$0.70
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$12.33
N/A
AVG Volume (30 Days)
107.1K
774.9K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,650,000.00
N/A
Revenue This Year
$128.77
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
132.17
N/A
52 Week Low
$1.20
$0.53
52 Week High
$12.15
$5.20

Technical Indicators

Market Signals
Indicator
EVAX
PPBT
Relative Strength Index (RSI) 44.27 40.16
Support Level $5.72 $0.67
Resistance Level $6.70 $0.87
Average True Range (ATR) 0.53 0.05
MACD -0.09 -0.01
Stochastic Oscillator 24.78 12.81

Price Performance

Historical Comparison
EVAX
PPBT

About EVAX Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: